Your session is about to expire
Understanding Stage 4 Liver Cancer
Treatment Options and Future Therapies for Advanced Liver Cancer
Advanced liver cancer presents a challenging scenario. However, multiple treatment options exist. Sorafenib, a targeted therapy, currently stands as a frontline treatment. It slows cancer growth but does not cure it. Other targeted therapies include lenvatinib, which works similarly by blocking the signals that make cancer cells grow.
Immunotherapy has changed the landscape for advanced liver cancer care. Drugs like nivolumab and pembrolizumab boost the immune system to fight the cancer cells more effectively. These treatments offer hope where traditional chemotherapies have limited effects.
For localized tumors, treatments such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and stereotactic body radiation therapy (SBRT) target specific areas without affecting healthy tissue significantly.
Research into advanced liver cancer is ongoing, with new therapies on the horizon promising better outcomes:
-
CAR-T cell therapy: A form of immunotherapy being studied in clinical trials involves modifying T-cells to better recognize and combat liver cancer cells.
-
Combination therapies: The use of different types of treatments, such as immunotherapy with targeted therapy or chemotherapy, shows potential in improving survival rates.
-
New drugs are under investigation in clinical trials designed to target specific mutations within liver cancer cells or disrupt their ability to grow and spread.
Patients may find clinical trials to be a source of cutting-edge treatments not yet widely available, contributing valuable information towards the pursuit of a cure for advanced liver cancer.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
Understanding and Survival Rates of Terminal Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a type of liver cancer that, when termed "terminal," indicates the cancer has advanced to a stage where treatments focus on symptom relief rather than cure. Survival rates provide a general guide and depend on factors such as the extent of cancer spread and overall health. In the terminal stages, survival rates are generally low.
The median survival time for terminal HCC ranges from 4 to 8 months without treatment, influenced by tumor size, liver function, and the presence of metastasis.
It's important to acknowledge:
- The outcome for each individual varies due to personal health factors.
- Palliative care can contribute to an improved quality of life in the terminal stages.
- Ongoing research continues to explore potential new treatments or management strategies.
This information serves to enhance understanding of terminal HCC, including the factors influencing survival rates and the role of palliative care.